Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 9/20 | 0.40 |
| ▸ | PPARA | Q07869 | 3/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
| ▸ | FABP3 | P05413 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.38 |
| ▸ | DHFR | P00374 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12828683 | 0.93 | LPAR2 (0.41) | PTGDR2PPARDPPARALPAR2TDP1 | |
| SCHEMBL1481081 | 0.89 | PTGDR2 (0.43) | PTGDR2LPAR2FFAR1 | |
| SCHEMBL1481080 | 0.89 | PTGDR2 (0.43) | PTGDR2LPAR2FFAR1 | |
| SCHEMBL12828681 | 0.85 | LPAR2 (0.42) | LPAR2TDP1LMNA | |
| SCHEMBL1480954 | 0.85 | PTGDR2 (0.43) | PTGDR2LPAR2FFAR1TDP1TSHR | |
| SCHEMBL1480949 | 0.85 | PTGDR2 (0.43) | PTGDR2LPAR2FFAR1TDP1TSHR | |
| SCHEMBL12829209 | 0.84 | FFAR4 (0.40) | FFAR1DHFR | |
| SCHEMBL12828682 | 0.82 | DPP4 (0.38) | TDP1LMNA | |
| SCHEMBL1481042 | 0.81 | PPARD (0.43) | PPARDFABP3FABP4LMNA | |
| SCHEMBL1481040 | 0.81 | PPARD (0.43) | PPARDFABP3FABP4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | PTPRS, PTPRO, PTPRJ | PTGDR2 1829/4885BACE1 4200/4885PPARD 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.